RNAZ News and Press, TransCode Therapeutics Inc. From 10/30/23

2023-10-30 16:42:47 ET More on TransCode Therapeutics TransCode shares plunge 20% on stock offering, Nasdaq compliance update TransCode Therapeutics announces public offering of common stock Historical earnings data for TransCode Therapeutics For further...

BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common...

2023-10-27 11:39:58 ET More on TransCode Therapeutics TransCode Therapeutics announces public offering of common stock TransCode Therapeutics reports Q2 results Seeking Alpha’s Quant Rating on TransCode Therapeutics Historical earnings data for Tr...

BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced The Nasdaq Hearings Panel (“Panel”) granted the Company...

2023-10-26 16:46:11 ET More on TransCode Therapeutics TransCode Therapeutics reports Q2 results Seeking Alpha’s Quant Rating on TransCode Therapeutics Historical earnings data for TransCode Therapeutics Financial information for TransCode Therapeutics ...

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an underwritten public offering of shares of its ...

2023-10-26 09:56:15 ET DENVER, Colo., Oct. 26, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; ABVC BioPharma Inc (NASDAQ: ABVC), PaxMedica Inc (NASDAQ: PXMD), TransCode Therapeutics Inc (NASDAQ: RNAZ), M...

2023-10-26 08:31:18 ET DENVER, Colo., Oct 26, 2023 ( www.247marketnews.com )- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) reported, this morning, improved survival in murine models bearing human glioblastoma multiforme (GBM) tumors treated with its lead therapeutic candidate, TTX-MC138....

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced significantly improved survival in murine models bearing human glioblastoma multiforme (GBM) tumors...

BOSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced preliminary results with its lead therapeutic candidate, TTX-MC138, in the first patient enrolled i...